Back to search

Netherlands· NL-6817b055eeaf

Gemcitabine SUN 1500 mg oplossing voor infusie

A gemcitabine product containing gemcitabinehydrochloride, registered in Netherlands by Sun Pharmaceutical Industries Europe B.V.. The same ATC class is registered in 17 of our 19 countries.

ATC L01BC05

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedGemcitabine SUN 1500 mg oplossing voo…ATCL01BC05REGISTER NO.NL-6817b055eeafPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Gemcitabine is registered in 17 of 19 countries.

Countries holding a registration under ATC L01BC05 (gemcitabine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose

Gemcitabine · ATC L01BC05

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of gemcitabine costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Gemcitabine · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$27.60
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
GEMCITABINEHYDROCHLORIDE
Manufacturer
Sun Pharmaceutical Industries Europe B.V.
Country
Netherlands (NL)
ATC code
L01BC05
ATC class
Gemcitabine
Defined daily dose
0.2 g, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    131077

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

370 interactions on record for gemcitabine.

Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Gemcitabine · interactions on record

370 records

  • 33 severe
  • 114 moderate
  • 19 minor
  • 204 info

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • CladribineL01BB04severe
  • PexidartinibL01EX15severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Gemcitabine in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All gemcitabine products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Gemcitabin Accord, Gemcitabin Ebewe
  • Belgium · Gemcitabin Sandoz, Gemcitabin Sun
  • Bulgaria · Гемсол, Гемцитабин Акорд
  • Cyprus · Gemcitabine Accord, Gemnil
  • Czechia · Gemcitabin Ebewe, Gemcitabin Sun
  • Germany · Bendacitabin, Gemci-Cell
  • Denmark · Gemcitabin "sandoz", Gemcitabin Accord
  • Estonia · Gemcitabine Accord, Gemcitabine Kabi
  • Spain · Gemcitabina Accord, Gemcitabina Aurovitas Spain
  • Finland · Gemcitabin Accord, Gemcitabin Sandoz
  • France · Gemcitabine Accord, Gemcitabine Arrow
  • United Kingdom (Northern Ireland) · Gemcitabine Accord Healthcare, Gemcitabine Ennogen Ip
  • Greece · Demozar, Gemcipen
  • Croatia · Gemcitabin Accord, Gemcitabin Sandoz
  • Hungary · Gemcitabin Kabi, Gemcitabine Accord
  • Ireland · Gemcitabine, Gemcitabine Accord Healthcare
  • Iceland · Gemcitabin Wh, Gemkabi
  • Italy · Gemcitabina Accord, Gemcitabina Aurobindo Pharma Italia
  • Lithuania · Gemcitabine Accord, Gemcitabine Kabi
  • Luxembourg · Gemcitabine Eg, Gemcitabine Eugia
  • Latvia · Gemcitabine Accord, Gemcitabine Kabi
  • Malta · Gemcitabine Pfizer Hellas, Gemnil
  • Norway · Gemcitabin Sandoz, Gemcitabin Sun
  • Poland · Gemcitabine Kabi, Gemcitabinum Accord
  • Portugal · Gemcit, Gemcitabina Accord
  • Romania · Gemcitabină Accord, Gemcitabina Kabi
  • Sweden · Gemcitabin Sandoz, Gemcitabin Sun
  • Slovenia · Gemcitabin Accord, Gemcitabin Kabi
  • Slovakia · Gemcitabín Sun, Gemcitabine Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bd9cc5a2-4a7e-45a1-8ffe-9d8932280bd6
GET /v1/drugs/bd9cc5a2-4a7e-45a1-8ffe-9d8932280bd6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h131077_smpc.pdf",
  "strength": null,
  "atc_label": "Gemcitabine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg131077",
  "excipients": [
    "NATRIUMCHLORIDE",
    "NATRIUMHYDROXIDE (E 524)",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "GEMCITABINEHYDROCHLORIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h131077.pdf",
  "authorised_at": "2023/06/16",
  "procedure_number": "NL/H/3313/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "131077",
  "additional_monitoring": "N"
}

See everything about gemcitabine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.